이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Preoperative and Postoperative Radiosurgery in Patients With Brain Metastases Undergoing Surgery (PREOPRAD)

2026년 11월 17일 업데이트: Paola Anna Jablonska, Fundacion Miguel Servet

Randomized Phase II/III Study Comparing Preoperative Radiosurgery Versus Postoperative Radiosurgery in Patients With Brain Metastases Eligible for Surgery: Correlation With Histopathological Factors and Radiomic Analysis.

The PREOP-RAD study aims to evaluate the feasibility, safety, and efficacy of preoperative surgical resection (SRS) in patients with large brain metastases requiring surgical resection, taking into account potential differences based on sex/gender, compared to postoperative SRS, within the Spanish healthcare context.

More specifically, the study seeks to:

  • Assess the clinical and radiological outcomes of the preoperative strategy in terms of local control, progression-free survival, and the occurrence of radionecrosis or neuromuscular dysfunction (nMD) compared to the postoperative strategy.
  • Study the histopathological profile of resected lesions before and after SRS, searching for personalized biomarkers of response and toxicity.
  • Identify patterns based on radiomic analysis and advanced imaging related to therapeutic response, recurrence, and complications.

PREOP-RAD is a prospective, randomized, multicenter study that will include patients diagnosed with symptomatic, single or multiple brain metastases ≥2 cm who are candidates for surgical resection. The procedure will consist of preoperative administration of SRS (1-5 fractions, depending on location and size), followed by surgery within a maximum of 10 days.

The intervention will be carried out in coordination with the Neurosurgery and Radiation Oncology Departments of each participating center, using a standardized workflow. The collection of surgical samples will allow for centralized histopathological studies. Furthermore, pre- and postoperative images will undergo radiomic analysis using artificial intelligence tools to explore similarities and correlate morphological and textural characteristics with clinical outcomes.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Preoperative SRS has emerged as a promising alternative. Administered before surgery, it allows for more precise planning, less exposure of healthy tissue, avoids delays due to surgical complications, and reduces the risk of neuromuscular dysfunction (nMD) by eliminating prior tumor manipulation. Recent retrospective studies and meta-analyses show local control rates similar to postoperative SRS, with a lower incidence of radionecrosis (1.5% vs. 14.6%) and nMD (3% vs. 17%). However, most of this data comes from North American centers, and prospective studies evaluating this strategy within the Spanish healthcare system, and especially its differentiated impact on patients by sex, are lacking.

연구 유형

중재적

등록 (추정된)

50

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Badajoz
      • Badajoz, Badajoz, 스페인, 06080
        • 아직 모집하지 않음
        • Hospital Universitario de Badajoz
        • 연락하다:
    • Galicia
      • Vigo, Galicia, 스페인, 36214
        • 아직 모집하지 않음
        • Hospital do Meixoeiro
        • 연락하다:
    • Madrid
      • Madrid, Madrid, 스페인, 28034
        • 모병
        • Hospital Universitario Ramón y Cajal
        • 연락하다:
      • Madrid, Madrid, 스페인, 28034
    • Navarre

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age ≥18 years.
  • Histologically confirmed solid tumor with one to four brain metastases.
  • At least one brain metastasis considered suitable for surgical resection and stereotactic radiosurgery.
  • Karnofsky Performance Status (KPS) ≥70.
  • Life expectancy ≥3 months.
  • Ability to undergo MRI examinations.
  • Written informed consent provided.

Exclusion Criteria:

  • Brain metastases from small-cell lung cancer, germ cell tumors, lymphoma, or leukemia.
  • Prior radiotherapy to the index lesion.
  • Leptomeningeal disease at baseline.
  • Contraindication to surgery or stereotactic radiosurgery.
  • Pregnancy or breastfeeding.
  • Any condition that, in the investigator's opinion, would interfere with study participation or evaluation.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 다른
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: preoperative radiosurgery

preoperative radiosurgery (SRS) in patients with brain metastases who are candidates for surgery

radiosurgery (SRS) in patients with brain metastases who are candidates for surgery

다른 이름들:
  • 방사선 수술

Microsurgical resection of the target brain metastasis, performed either after preoperative SRS or before postoperative SRS depending on treatment arm

다른: postoperative radiosurgery

standard treatment, consisting of surgical resection followed by irradiation of the tumor bed

radiosurgery (SRS) in patients with brain metastases who are candidates for surgery

다른 이름들:
  • 방사선 수술

Microsurgical resection of the target brain metastasis, performed either after preoperative SRS or before postoperative SRS depending on treatment arm

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Locoregional adverse event-free survival
기간: From randomization to the first locoregional adverse event, assessed up to 12 months after randomization

A side effect or complication occurring specifically in the region or site where a medical procedure or treatment-such as surgery or radiotherapy-was performed.

From randomization to the first locoregional adverse event, assessed up to 12 months after randomization

2차 결과 측정

결과 측정
측정값 설명
기간
Meningeal Failure Rate
기간: 6 and 12 months after randomization.

Proportion of patients developing nodular meningeal disease (nMD) during follow-up, as determined by clinical assessment and brain magnetic resonance imaging (MRI).

6 and 12 months after randomization.
Symptomatic Radiation Necrosis Rate
기간: 6 and 12 months after randomization.

Proportion of patients developing symptomatic radiation necrosis confirmed by clinical and radiological evaluation.

6 and 12 months after randomization.
Local Control Rate
기간: 6 and 12 months after randomization.

Proportion of patients without local recurrence at the treated lesion or surgical cavity, as assessed by brain MRI.

6 and 12 months after randomization.
Distant Brain Failure-Free Survival
기간: 6 and 12 months after randomization.

Time from randomization to the occurrence of distant intracranial failure, defined as the appearance of new brain metastases outside the treated lesion(s).

6 and 12 months after randomization.
Overall Survival
기간: 6 and 12 months after randomization.

Time from randomization to death from any cause.

6 and 12 months after randomization.

기타 결과 측정

결과 측정
측정값 설명
기간
Time to Whole-Brain Radiotherapy (WBRT)
기간: From randomization until administration of WBRT, up to 42 months.

Time from randomization to the administration of whole-brain radiotherapy (WBRT).

From randomization until administration of WBRT, up to 42 months.
Health-Related Quality of Life
기간: Baseline, and at 3, 6, 12, 18, and 24 months after treatment.

Change from baseline in health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Brain Neoplasm 20 (EORTC QLQ-BN20). The questionnaire includes 20 items organized into 4 disease-specific symptom scales (future uncertainty, visual disorder, motor dysfunction, communication deficit) and 7 single items. All scores are linearly transformed to a scale from 0 to 100, where a higher score represents a higher level of symptoms or worse outcome (greater symptom burden).

Baseline, and at 3, 6, 12, 18, and 24 months after treatment.
Length of Hospital Stay
기간: From the date of admission for the surgical procedure until the date of hospital discharge, assessed up to 30 days.

Duration of hospital stay measured in days, defined as the time from the date of hospital admission for the surgical procedure until the date of hospital discharge.

From the date of admission for the surgical procedure until the date of hospital discharge, assessed up to 30 days.
Treatment Delay
기간: From treatment planning to treatment completion, up to 42 months.

Time elapsed between the protocol-defined optimal treatment schedule and the actual administration of treatment.

From treatment planning to treatment completion, up to 42 months.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 9월 30일

기본 완료 (추정된)

2030년 3월 30일

연구 완료 (추정된)

2030년 3월 31일

연구 등록 날짜

최초 제출

2026년 11월 3일

QC 기준을 충족하는 최초 제출

2026년 11월 17일

처음 게시됨 (실제)

2026년 11월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 17일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • PREOPRAD

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .